WASHINGTON, DC: Weber Shandwick aided Genentech on communications work leading to approval from the Food and Drug Administration (FDA) of Avastin, a drug used in treating metastatic breast cancer, sources told PRWeek. On February 22, the FDA gave the biotech company permission in a surprising move that went against the advice of its own advisory panel.
Genentech and WS did not return calls for comment on communication efforts leading up to its approval by press time. The FDA's decision was an ...